All Interventions

    Hyperbaric Oxygen Therapy

    Therapies
    Oxygen Therapies

    Breathing pure oxygen in a pressurized chamber to enhance tissue oxygenation, promote healing, and stimulate stem cell mobilization.

    Evidence Summary

    8
    / 10Score
    Strong
    Good Clinical Evidence

    Hyperbaric oxygen therapy (HBOT) has robust randomized-trial support across more than a dozen FDA-approved indications, and the evidence base for cognitive and cellular-aging applications has continued to strengthen through 2025–2026. A 2026 systematic review and meta-analysis of 35 randomized controlled trials (3,036 participants) found that adding HBOT to standard care for post-stroke cognitive impairment improved cognitive scores versus control — a pooled mean gain of +2.90 points on the MoCA (95% CI 2.47–3.33) and +2.68 points on the MMSE (95% CI 2.20–3.16) — though the authors graded the certainty of evidence as low, with high between-study heterogeneity and all included trials conducted in China (Hu et al., Frontiers in Neurology, 2026). A 2025 phase II double-blind, sham-controlled randomized trial in adults with persistent symptoms after brain injury (47 analyzed) reported a greater reduction in total neurobehavioral symptoms after 40 sessions at 1.5 ATA than sham (between-group difference 7.0 points, 95% CI 1.7–12.3, p=0.01), with blinding validated by chance-level allocation guesses (Weaver et al., Scientific Reports, 2025). These build on earlier work in healthy aging adults, where 60 daily sessions at 2 ATA were associated with increased leukocyte telomere length (up to ~38% in B cells) and roughly a one-third reduction in senescent T-helper cells (Hachmo et al., Aging, 2020), and with cognitive gains in attention and information-processing speed (net effect sizes 0.75–0.79; Hadanny et al., Aging, 2020). Overall these findings are promising but derive from small-to-moderate trials and, for longevity endpoints, remain early-stage; HBOT for cognition and healthy aging is investigational, is not a cure, and should be delivered only under qualified medical supervision after screening for contraindications.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    Increases dissolved oxygen in plasma by 10-15x, stimulating angiogenesis, reducing inflammation, mobilizing stem cells, and enhancing mitochondrial function through hypoxia-inducible factor (HIF) pathway modulation.

    Who Is This For?

    Non-healing wounds, post-radiation, TBI/concussion, anti-aging protocols. Baseline assessment recommended.

    Protocol & Dosing

    Dose

    1.5-3.0 ATA pressure. Pure oxygen or enriched air depending on protocol.

    Frequency

    Daily to 3x/week

    Duration

    20-60 sessions typical

    Protocol Summary

    Sessions in pressurized chamber at 1.5-3.0 ATA for 60-90 minutes. Protocol varies by indication.

    Latest Evidence

    2025–2026: cognitive, cellular-aging & post-injury evidence

    A 2026 systematic review and meta-analysis of 35 randomized controlled trials (3,036 participants) found that adding hyperbaric oxygen therapy to standard care for post-stroke cognitive impairment improved cognitive scores versus control — a pooled gain of +2.90 points on the MoCA and +2.68 on the MMSE — though the authors rated the certainty of evidence as low, with high heterogeneity and all trials conducted in China. A 2025 phase II double-blind, sham-controlled randomized trial in adults with persistent symptoms after brain injury found a greater reduction in total neurobehavioral symptoms after 40 sessions at 1.5 ATA than sham (between-group difference 7.0 points, 95% CI 1.7–12.3, p=0.01), with blinding confirmed. These build on an earlier prospective trial in healthy aging adults in which 60 sessions at 2 ATA were associated with longer immune-cell telomeres and fewer senescent T-cells.

    These are small-to-moderate trials and, for longevity endpoints, largely early-stage. HBOT for cognition and healthy aging is investigational, is not a cure, and is delivered only under qualified medical supervision after screening for contraindications such as untreated pneumothorax. Educational information, not medical advice.

    Prospective trial · n=30

    Telomere length increase after HBOT

    Source: Hachmo et al., Aging (Albany NY), 2020 — 30 healthy aging adults, 60 daily sessions at 2 ATA. Telomere length change from baseline measured after HBOT.

    Latest Evidence · 2026 Meta-analysis

    HBOT and cognitive scores: 2026 meta-analysis

    Pooled mean improvement in cognitive scores when HBOT is added to standard care for post-stroke cognitive impairment, across 35 randomized trials (3,036 patients). Higher is better. GRADE certainty: low.

    Source: Hu et al., Frontiers in Neurology, 2026 (meta-analysis of 35 RCTs).

    Key references: HBOT for post-stroke cognitive impairment: systematic review & meta-analysis — Front. Neurol. (2026) · Double-blind sham-controlled RCT of HBOT after brain injury — Scientific Reports (2025) · HBOT increases telomere length & reduces immunosenescence — Aging (2020) · HBOT for Alzheimer's disease: systematic review & meta-analysis — Front. Aging Neurosci. (2024) · Long-term outcomes of HBOT in post-COVID condition (RCT follow-up) — Scientific Reports (2024)

    Interactions & Precautions

    Contraindications

    • Untreated pneumothorax
    • Active malignancy (relative)
    • Claustrophobia
    • Certain medications

    Potential Risks

    • •Barotrauma
    • •Oxygen toxicity at high pressures
    • •Fire hazard in chamber

    Potential Side Effects

    Ear barotrauma
    Temporary myopia
    Fatigue
    Rare: oxygen toxicity seizure

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Screen for contraindications. Soft chambers (1.3 ATA) offer milder alternative. Consider 40-session protocols for neurological applications.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Cost & Access

    Cost Range

    $$$

    Accessibility

    Specialty clinics

    Availability varies by location

    Database index
    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation